# Lenalidomide for Adult Histiocyte Disorders

> **NCT02523040** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- Langerhans Cell Histiocytosis (LCH)
- Histiocytoses Erdheim-chester Disease
- Histiocytic Sarcoma (HS)

## Interventions

- **DRUG:** Lenalidomide

## Key facts

- **NCT ID:** NCT02523040
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-08
- **Primary completion:** 2024-02
- **Final completion:** 2026-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02523040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02523040, "Lenalidomide for Adult Histiocyte Disorders". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02523040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*